Anthrax Vaccine Market - By Type: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines. By Application: Pre-exposure Vaccination, Post-exposure Vaccination. By End-user: Military, Government, Healthcare Providers, Others. By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The global Anthrax Vaccine Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.8 billion by 2031, growing at a CAGR of 11.3%. The market is driven by biodefense preparedness, next-generation vaccine development, and increasing zoonotic transmission risks.
2024 Market Breakthroughs
Market Drivers
1. Biodefense Spending
2. Livestock Outbreaks
3. Military Demand
Competitive Landscape
|
Company |
Market Share |
Flagship Product |
Strategic Edge |
|
Emergent BioSolutions |
55% |
BioThrax®/AV7909 |
US government primary supplier |
|
Bavarian Nordic |
20% |
mRNA-based candidate |
Rapid pandemic-scale production |
|
Oragenics |
10% |
TerraCoV2-AM |
Dual-pathogen approach |
Emerging Disruptors:
Market Segmentation
Recent Developments (2024)
Need help?
Chat with our team in a minute.